Quiero saber acerca de...

Federal Register / Vol. 86, No. 59 / Tuesday, March 30, 2021 / Proposed Rules this AD requires performing the corrective action in accordance with FAA-approved procedures.
3 Where paragraph 4 of EASA AD 2018
0284 specifies an alternative method to comply with the requirements of paragraph 3 of EASA AD 20180284 by replacing an affected part, this AD requires removing the affected part from service as an alternative method.
4 Where paragraph 1 of EASA AD 2018
0284 specifies a compliance time of 3
months or 50 flight hours, whichever occurs first, this AD requires a compliance time of within 50 hours time-in-service TIS from the effective date of this AD.
5 Where paragraph 2 of EASA AD 2018
0284 specifies a compliance time of 15
days, this AD requires using a compliance time of 30 days.
6 The Remarks section of EASA AD
20180284 does not apply to this AD.
i Alternative Methods of Compliance AMOCs 1 The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph j2 of this AD.
Information may be emailed to: 9-AVS-AIR730-AMOC@faa.gov.
2 Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/
certificate holding district office.

jbell on DSKJLSW7X2PROD with PROPOSALS

j Related Information 1 For EASA AD 20180284, contact the EASA, Konrad-Adenauer-Ufer 3, 50668
Cologne, Germany; telephone +49 221 8999
000; email ADs@easa.europa.eu; internet www.easa.europa.eu. You may find this EASA AD on the EASA website at https
ad.easa.europa.eu. You may view this material at the FAA, Office of the Regional Counsel, Southwest Region, 10101 Hillwood Pkwy., Room 6N321, Fort Worth, TX 76177.
For information on the availability of this material at the FAA, call 8172225110. This material may be found in the AD docket on the internet at https www.regulations.gov by searching for and locating Docket No.
FAA20210199.
2 For more information about this AD, contact Katherine Venegas, Aviation Safety Engineer, Los Angeles ACO Branch, FAA, 3960 Paramount Blvd., Lakewood, California 90712; telephone 562 6275353; email katherine.venegas@faa.gov.
Issued on March 24, 2021.
Lance T. Gant, Director, Compliance & Airworthiness Division, Aircraft Certification Service.
FR Doc. 202106473 Filed 32921; 8:45 am BILLING CODE 491013P

VerDate Sep<11>2014

16:16 Mar 29, 2021

Jkt 253001

DEPARTMENT OF JUSTICE
Drug Enforcement Administration 21 CFR Part 1308
Docket No. DEA491

Schedules of Controlled Substances:
Placement of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA and FUB-144 in Schedule I
Drug Enforcement Administration, Department of Justice.
ACTION: Notice of proposed rulemaking.
AGENCY:

The Drug Enforcement Administration proposes placing ethyl 2-1-5-fluoropentyl-1H-indazole-3carboxamido-3,3-dimethylbutanoate trivial name: 5F-EDMB-PINACA;
methyl 2-1-5-fluoropentyl-1H-indole3-carboxamido-3,3-dimethylbutanoate trivial name: 5F-MDMB-PICA; Nadamantan-1-yl-1-4-fluorobenzyl-1Hindazole-3-carboxamide trivial names:
FUB-AKB48; FUB-APINACA; AKB48 N4-fluorobenzyl; 1-5-fluoropentyl-N2-phenylpropan-2-yl-1H-indazole-3carboxamide trivial names: 5F-CUMYLPINACA; SGT-25; and 1-4fluorobenzyl-1H-indol-3-yl2,2,3,3tetramethylcyclopropylmethanone trivial name: FUB-144, including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess or propose to handle 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144.
DATES: Comments must be submitted electronically or postmarked on or before April 29, 2021.
Requests for hearing and waivers of an opportunity for a hearing or to participate in a hearing must be received on or before April 29, 2021.
ADDRESSES: To ensure proper handling of comments, please reference Docket No. DEA491 on all electronic and written correspondence, including any attachments.
Electronic comments: Interested persons may file written comments on this proposal in accordance with 21 CFR
1308.43g. The Drug Enforcement Administration DEA encourages that all comments be submitted SUMMARY:

PO 00000

Frm 00006

Fmt 4702

Sfmt 4702

16553

electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments.
Please go to http www.regulations.gov and follow the on-line instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously available for public view on http
www.regulations.gov. If you have received a Comment Tracking Number, your comment has been submitted successfully, and there is no need to resubmit the same comment.
Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
Paper comments: Paper comments that duplicate electronic submissions are not necessary and are discouraged.
Should you wish to mail a paper comment in lieu of an electronic comment, send via regular or express mail to: Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia 22152.
Hearing requests: All requests for a hearing and waivers of participation, together with a written statement of position on the matters of fact and law asserted in the hearing, must be sent to:
Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing and waivers of participation should also be sent to: 1 Drug Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and 2 Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW 8701 Morrissette Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT:
Terrence L. Boos, Drug and Chemical Evaluation Section, Drug Enforcement Administration; Telephone: 571 362
3249.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments Please note that all comments received in response to this docket are considered part of the public record.
They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration DEA for public inspection online at http
www.regulations.gov. Such information includes personal identifying
E:FRFM30MRP1.SGM

30MRP1